Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Lucentis

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Lucentis was produced by Novartis and Roche.

FDA approves Coherus’ Cimerli as biosimilar interchangeable with Lucentis for all five indications

FDA approves Coherus’ Cimerli as biosimilar interchangeable with Lucentis for all five indications

The FDA’s decision is based on a comprehensive analytical, preclinical and clinical programme – including the COLUMBUS-AMD study – to confirm equivalent safety and efficacy to Lucentis. ... Cimerli is not anticipated to result in safety risk or

Novartis sees demand returning to pre-COVID-19 levels in Q2 results

Novartis sees demand returning to pre-COVID-19 levels in Q2 results growth of heart failure drug Entresto (sacubitril and valsartan), monoclonal antibody Cosentyx (secukinumab), gene therapy Zolgensma (onasemnogene abeparvovec), wet AMD therapy Lucentis (ranibizumab) and multiple sclerosis drug Kesimpta (ofatumumab).

Novartis stumbles in Q2 as COVID-19 impacts sales

Novartis stumbles in Q2 as COVID-19 impacts sales That includes its wet AMD drug Lucentis (ranibizumab), which fell 25% to bring in $401m in the quarter.

Bayer shares dip as Novartis gets EU okay for Beovu in wet AMD

Bayer shares dip as Novartis gets EU okay for Beovu in wet AMD aflibercept) squaring off against Novartis’ older drug Lucentis (ranibizumab), the first VEGF inhibitor for wet AMD to reach the market. ... Novartis’ sales of Lucentis managed a slight gain overall in 2019 to just over $2bn, but fell slightly in the

Biogen takes on Lucentis, Eylea biosimilars from Samsung joint venture

Biogen takes on Lucentis, Eylea biosimilars from Samsung joint venture Lucentis was the first VEGF inhibitor to reach the market for wet AMD and grew quickly into a blockbuster product with sales of around $3.7bn last year. ... Alteogen and Momenta/Mylan have versions of Eylea in development, while Coherus and Xbrane Pharma

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Report: Reinventing product and portfolio value for the biopharmaceutical industry
Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of...
Neil Thompson
How AI is finally helping rare diseases gain more than just attention
By Neil Thompson...
Is communication failing us?
Compelling people to care in a world oversaturated with news and information...